Needham analyst Ami Fadia has reiterated their neutral stance on BIIB stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia has given his Hold rating due to a combination of factors impacting Biogen’s current and future performance. The decision reflects concerns about ongoing challenges, particularly with the company’s key products and pipeline. The slow market uptake of Leqembi and the pressures facing Skyclarys are significant headwinds that contribute to a cautious outlook.
Additionally, the lack of new pipeline catalysts this year adds to the uncertainty surrounding Biogen’s growth prospects. Fadia is looking for more clarity on the company’s stabilization and potential growth, especially through management’s comments on business development and market dynamics in upcoming earnings calls. This cautious stance is reflected in the revised earnings estimates for both the upcoming quarter and the full year 2025.
In another report released yesterday, Bank of America Securities also reiterated a Hold rating on the stock with a $147.00 price target.